Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Misoo C Ellison

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Open Forum Infectious Diseases|August 4, 2019
Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/IIMark H Wilcox, Galia Rahav, Erik R Dubberke, et al.
Journal of the American Medical Informatics Association : JAMIA|July 3, 2010
Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients' need for symptom management support: a randomized clinical trialCornelia M Ruland, Harald H Holte, Jo Røislien, et al.
Diabetes, Obesity & Metabolism|July 24, 2020
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studiesRichard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, et al.
The Journal of Experimental Medicine|August 17, 2005
Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiencyWilliam H Wheat, Carlyne D Cool, Yoshikazu Morimoto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2018
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for RecurrenceDale N Gerding, Ciaran P Kelly, Galia Rahav, et al.
Human Vaccines & Immunotherapeutics|January 22, 2025
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studiesAnna R Giuliano, Joel M Palefsky, Stephen E Goldstone, et al.
European Urology Oncology|May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance StatusPetros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
JAMA|November 29, 2016
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in WomenOle-Erik Iversen, Maria Jose Miranda, Angels Ulied, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|April 24, 2020
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitusJie Liu, Lisa Tarasenko, Annpey Pong, et al.
Open Forum Infectious Diseases|August 4, 2019
Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/IIMark H Wilcox, Galia Rahav, Erik R Dubberke, et al.
Journal of the American Medical Informatics Association : JAMIA|July 3, 2010
Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients' need for symptom management support: a randomized clinical trialCornelia M Ruland, Harald H Holte, Jo Røislien, et al.
Diabetes, Obesity & Metabolism|July 24, 2020
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studiesRichard Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, et al.
The Journal of Experimental Medicine|August 17, 2005
Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiencyWilliam H Wheat, Carlyne D Cool, Yoshikazu Morimoto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2018
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for RecurrenceDale N Gerding, Ciaran P Kelly, Galia Rahav, et al.
Human Vaccines & Immunotherapeutics|January 22, 2025
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studiesAnna R Giuliano, Joel M Palefsky, Stephen E Goldstone, et al.
European Urology Oncology|May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance StatusPetros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
JAMA|November 29, 2016
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in WomenOle-Erik Iversen, Maria Jose Miranda, Angels Ulied, et al.
Pageof 5